Cytox is a world-leader in developing and commercialising polygenic risk scoring (PRS) algorithms to characterise an individual’s genetic risk for developing Alzheimer's disease. A polygenic risk score, also called a polygenic score, genetic risk score, hazard score or genome-wide score, provides a probability of a disease trait arising, based on multiple genetic loci and their associated disease-causing weights.

Cytox’s products to characterise Alzheimer’s disease assess several hundred thousand  single nucleotide polymorphisms (SNPs) to generate a PRS that provides a probability, as determined by an individual’s genetics, of disease occuring, and projected timings for the onset of disease.

Cytox's approaches are being actively evaluated today by global pharma, biotech and sponsors of larger cohort studies as a more rigorous and cost-effective means to improve stratification of at-risk subjects for participation in clinical trials.